UCB is pleased to announce that 25 scientific abstracts have been accepted for poster presentation at the upcoming 71st American Epilepsy Society (AES) Annual Meeting, which takes place from 1-5 December in Washington, D.C., USA.1-25
Posters being presented further describe VIMPAT® (lacosamide) CV and BRIVIACT® (brivaracetam) CV clinical data,1-11 including results from a recently concluded placebo-controlled trial which studied VIMPAT® as adjunctive therapy in children aged four years and older and adolescents with uncontrolled focal (partial-onset) seizures,4 and updated data on the safety and tolerability of long-term treatment with adjunctive BRIVIACT® for focal seizures.9
UCB will also present preliminary data on two UCB developmental drug candidates for epilepsy, padsevonil and radiprodil.12-19
Additional presentations will share a wide range of data, including results from a social media survey to assess perceptions of patient information leaflets, and pre-clinical data identifying a potential target receptor for epilepsy therapy.20-25
Alongside scientific presentations, UCB will be facilitating conversations with delegates throughout the meeting, focusing on rising above expectations of care for people with epilepsy. Harnessing innovative technologies, such as virtual reality seizure simulation, UCB is encouraging collaborations which may address the challenges faced by people living with epilepsy, and sharing real-world examples of positive programs and partnerships such as the UCB Family Epilepsy Scholarship ProgramTM and Canine AssistantsTM partnership. At AES, UCB will further demonstrate and reinforce its neurology passion, expertise and commitment to the goal of addressing and improving the lived experiences of people with epilepsy.
“At UCB, we strive to develop solutions that help patients achieve their treatment goals, and to support the wider epilepsy community in elevating the overall patient experience. We are excited to showcase the scale and passion of our commitment at AES” said Jeff Wren, Head of UCB’s Neurology Patient Value Unit. “We have a longstanding heritage in epilepsy and take pride in the breadth and depth of our research we share each year at AES. This year is no exception, and we’re very excited to contribute our expertise to help support patients live their lives at their ideal.”
In the U.S., VIMPAT® is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT® injection in pediatric patients has not been established, VIMPAT® injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older).26
In the EU, VIMPAT® is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.27
In the U.S., BRIVIACT® is indicated for the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.28
In the EU, BRIVIACT® is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.29
Additional label and important safety information about VIMPAT® and BRIVIACT® can be found below.26-29
For further information:
Corporate Communications
France Nivelle
Global Communications, UCB
T +32.2.559.9178
france.nivelle@ucb.com
Jim Baxter,
Neurology Communications, UCB
T+32.2.473.78.85.01
jim.baxter@ucb.com
Investor Relations
Antje Witte
Investor Relations, UCB
T +32.2.559.94.14
antje.witte@ucb.com
Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588,
isabelle.ghellynck@ucb.com
About UCB
UCB, Brussels, Belgium is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels